Dr. Rao highlights personalized care for rare brain vascular disorder dAVFs

USA-trained neurosurgeon Dr. Mohana Rao Patibandla says international research is helping doctors better match treatment to the risk profile of dural arteriovenous fistulas, rare brain vascular lesions that can cause tinnitus, headaches, seizures or hemorrhage. The message: multidisciplinary planning, not a one-size-fits-all procedure, is increasingly shaping safer outcomes for patients in India and worldwide.

Why it matters: - Dural arteriovenous fistulas, or dAVFs, can be benign in some patients and life-threatening in others. - Better risk stratification can help physicians choose between observation, embolization, surgery or stereotactic radiosurgery. - Earlier diagnosis and individualized treatment can reduce the risk of neurological injury and brain hemorrhage.

What happened: - Dr. Mohana Rao Patibandla, founder and chief neurosurgeon of Dr. Rao's Hospital – International Institute of Neurosciences in Guntur, used a July 2026 release to explain how international dAVF research is changing patient care. - Dr. Rao said his U.S. fellowship training and participation in multicenter research helped translate evidence into practical treatment decisions. - The release cites collaboration through the Consortium for Dural Arteriovenous Fistula Outcomes Research and the International Gamma Knife Research Foundation. - Dr. Rao's Hospital says it uses a multidisciplinary team to evaluate cerebrovascular patients.

The details: - dAVFs are abnormal connections between arteries and veins in the dura mater, the membrane surrounding the brain. - The lesions usually develop later in life, unlike congenital brain arteriovenous malformations. - Middle-aged and older adults are most commonly affected. - Potential triggers include venous sinus thrombosis, trauma, surgery or other vascular changes. - Many patients have no clearly identifiable cause. - Symptoms can include pulsatile tinnitus, headaches, blurred or double vision, eye redness or swelling, seizures, weakness, numbness, speech difficulty, balance problems and sudden severe headache. - Diagnosis is often delayed because patients may first see ear, eye or neurology specialists. - Blood flow in dAVFs bypasses a normal capillary network and enters veins under increased pressure. - Venous drainage pattern is one of the most important factors in determining risk and treatment strategy. - Low-risk fistulas may be monitored. - Higher-risk fistulas may need prompt intervention because of bleeding or neurological decline. - Modern treatment options include endovascular embolization, microsurgery, stereotactic radiosurgery and observation. - Endovascular embolization uses a catheter and embolic material to close the fistula. - Microsurgery can provide immediate disconnection when anatomy is too complex for embolization alone. - Stereotactic radiosurgery delivers focused radiation and causes gradual closure over months or years. - Radiosurgery may be useful for residual fistulas, surgically difficult lesions or patients with higher surgical risk. - Follow-up imaging remains important after radiosurgery during the latency period. - The release says CONDOR combined data from more than 1,000 patients and created the world's largest clinical registry of dAVFs. - One CONDOR study found embolization improved complete obliteration and lowered hemorrhage and death risk in high-grade, unruptured dAVFs compared with conservative management. - Another CONDOR finding identified recurrence risk after apparent cure and supported scheduled angiographic follow-up, especially in the first few years after treatment. - The release says international Gamma Knife research found stereotactic radiosurgery can produce durable obliteration with a low risk of permanent complications in selected patients.

Between the lines: - The central shift is from procedural availability to evidence-based selection of the right procedure for the right patient. - Rare diseases like dAVFs are hard for single centers to study, so international registries are driving more reliable treatment guidance. - The release argues that AI and advanced imaging may improve planning, but they do not replace multidisciplinary judgment. - Dr. Rao's message is that durable outcomes depend on anatomy, hemorrhage risk, symptoms, patient preferences and long-term surveillance.

What's next: - The release points to continued growth in AI, high-resolution imaging, endovascular tools, stereotactic radiosurgery and precision medicine for dAVF care. - Ongoing research is expected to refine who should be observed, who should be treated and which combination of therapies offers the best outcome. - The hospital says patients with pulsatile tinnitus, unexplained headaches, seizures, visual changes or other neurological symptoms should seek evaluation at a comprehensive neuroscience center.

The bottom line: - For dAVFs, the key change is not just better tools. It is better matching of treatment to risk, anatomy and follow-up needs.